V

VA Northern California Health Care System | Sacramento VA Medical Center

Research site

(Unclaimed)

Location

10535 Hospital Way, Bldg 700, Rm- 5A038, Mather, California, United States of America

Site insights

Top conditions

Top treatments

Ozanimod

Contezolid Acefosamil

Contezolid

Timolol

Linezolid

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 19 total trials

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Active, not recruiting

Crohn Disease

Other: Placebo

Drug: Ozanimod

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Active, not recruiting

Crohn Disease

Drug: Ozanimod

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debri...

Enrolling

Diabetic Foot Infection

Non-healing Wound

Biological: TTAX01

Other: Standard care

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03)

The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with interm...

Active, not recruiting

Prostate Cancer

Biological: Placebo + valacyclovir

Biological: Aglatimagene besadenovec + valacyclovir

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linez...

Enrolling

Diabetic Foot Infection

Drug: Linezolid (IV and PO)

Drug: contezolid acefosamil (IV)/contezolid (PO)